Fundraising Fox
Dianthus Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 127 employees on LinkedIn · 1 known investors
Find your way into Dianthus Therapeutics
Sign up to see every warm intro you have to Dianthus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dianthus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.
Founders & leadership
Dianthus Therapeutics was founded in 2019 by Jonathan Violin.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$121.5M disclosed across 4 rounds · 2019–2022
▶$100MraisedApr 2022 · 22 investors · BiotechnologyRule 506(b)
- Tomas KiselakDirector
- Kenneth Evan ThompsonExecutive Officer
- Paula SoteropoulosDirector
- Jonathan ViolinDirector
- Leon O. Moulder, Jr.Director
- Lei MengDirector
- Marino GarciaExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $3M
- Placement agents
- Jefferies LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$15MraisedJun 2021 · 6 investors · BiotechnologyRule 506(b)
- Tomas KiselakDirector
- Leon O. Moulder, Jr.Director
- Kenneth Evan ThompsonExecutive Officer
- Jonathan ViolinExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$7.7KraisedApr 2021 · 1 investors · BiotechnologyRule 506(b)
- Kenneth Evan ThompsonExecutive Officer
- Jonathan ViolinExecutive Officer, Director
- Leon MoulderDirector
- Offering amount
- $7.7K
- Amount sold
- $7.7K
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6.5MraisedDec 2020 · 6 investors · BiotechnologyRule 506(b)
- Leon Moulder, Jr.Director
- Jonathan ViolinExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $6.5M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Dianthus Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Dianthus Therapeutics do?
- Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.
- Who founded Dianthus Therapeutics?
- Dianthus Therapeutics was founded by Jonathan Violin in 2019.
- Who are Dianthus Therapeutics's investors?
- Dianthus Therapeutics's investors include 5AM Ventures.
- How much funding has Dianthus Therapeutics raised?
- Dianthus Therapeutics has disclosed $121.5M raised across 4 rounds.
- Where is Dianthus Therapeutics headquartered?
- Dianthus Therapeutics is headquartered in Waltham, US.